Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2018

View Archived Issues

Immix studies IMX-110 in patients with advanced solid tumors

Global BioLife completes Zaire Ebola research portion for study of LB-2

CXCR2 targeting suppresses allergic airway inflammation in mice

Magenta and Heidelberg Pharma sign exclusive multi-target research agreement

Zynerba plans pivotal study with ZYN-002 in fragile X syndrome

Vividion and Celgene enter strategic research collaboration

G1 Therapeutics reports phase IIa data on trilaciclib in extensive-stage SCLC

Promising topline data from pivotal phase III study of CLS-TA in uveitic macular edema

AEC syndrome pathology linked to protein aggregation of the p63 transcription factor

Phase III trials of olumacostat glasaretil for acne do not meet co-primary endpoints

FDA grants rare pediatric disease designation to Prometic's inter-alpha inhibitor proteins

Aminoacyclase-1 is a novel potential biomarker for schizophrenia

Enrollment begins in phase I study of treprostinil Technosphere

Safety, eosinophil reductions encourage further development of AK-002

Sorrento reports initial data from phase Ib study of autologous anti-CEA CAR T cells

Enteris signs feasibility development agreement with Ferring

Chi-Med initiates proof-of-concept study of epitinib in glioblastoma

Sanifit completes phase II trial of SNF-472 for calciphylaxis in patients on dialysis

Researchers mimic human walnut allergy in mice

Nightstar Therapeutics initiates phase III STAR trial of NSR-REP1 for choroideremia

Novel tubulin polymerization inhibitors discovered at Athenex

Merck & Co. patents new HCV NS5B inhibitors

Orbis Health Solutions presents anti-CTLA4 and PD-1-encoding bead vectors

Immatics Biotechnologies divulges novel constructs binding COL6A3 antigens

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...